Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma

[1]  Michael R. Green,et al.  A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. , 2013, International journal of radiation oncology, biology, physics.

[2]  Susan M. Chang,et al.  Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. , 2012, Neuro-oncology.

[3]  D. Cheresh,et al.  VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. , 2012, Cancer cell.

[4]  J. Hainsworth,et al.  Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. , 2012, Clinical advances in hematology & oncology : H&O.

[5]  Paul S Mischel,et al.  Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Sagar Agarwal,et al.  The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain , 2011, Journal of Pharmacology and Experimental Therapeutics.

[7]  J. Hainsworth,et al.  Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first‐line treatment of patients with glioblastoma multiforme , 2010, Cancer.

[8]  K. Flaherty,et al.  Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases , 2009, Clinical Cancer Research.

[9]  A. Ashworth,et al.  Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas , 2009, British Journal of Cancer.

[10]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[11]  V. D’Hondt,et al.  Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. , 2008, The oncologist.

[12]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[13]  Dieta Brandsma,et al.  Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide , 2008, Cancer.

[14]  M. Delorenzi,et al.  Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. , 2008, The Journal of molecular diagnostics : JMD.

[15]  K. Flaherty,et al.  Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. , 2007, Cancer research.

[16]  Andreas von Deimling,et al.  Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. , 2007, Neuro-oncology.

[17]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[18]  S. Wilhelm,et al.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.

[19]  R. Pazdur,et al.  Sorafenib for the Treatment of Advanced Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[20]  A. Paetau,et al.  Amplification of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas , 2006, Molecular Cancer Research.

[21]  H. Joensuu,et al.  Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme , 2005, The Journal of pathology.

[22]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[23]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[24]  M. Rosenblum,et al.  Dose-Dependent Effects of Platelet-Derived Growth Factor-B on Glial Tumorigenesis , 2004, Cancer Research.

[25]  G. Broggi,et al.  Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma , 2003, Journal of Neuro-Oncology.

[26]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[27]  Dobb's journal staff.  Of interest , 2001, Administration in mental health.

[28]  C. Heldin,et al.  Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.

[29]  A. Friedman,et al.  Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. , 2012, International journal of radiation oncology, biology, physics.

[30]  R. McLendon,et al.  Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma , 2010, Journal of Neuro-Oncology.